Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Stories Sponsored Addressing the next wave of COVID-19 through a new approach to vaccines Fronts Teaser Ocugen remains diligent in developing innovative COVID-19 vaccine options to meet the current need and prepare for an annual booster strategy. Sponsored by Ocugen Sponsored Potential Modifier Gene Therapy for Degenerative Retinal Diseases Fronts Teaser Modifier gene (NR2E3), a potential gene agnostic therapeutic, could reverse inherited retinal dystrophies (IRDs) with multiple gene mutations Sponsored by Ocugen
Sponsored Addressing the next wave of COVID-19 through a new approach to vaccines Fronts Teaser Ocugen remains diligent in developing innovative COVID-19 vaccine options to meet the current need and prepare for an annual booster strategy. Sponsored by Ocugen
Sponsored Potential Modifier Gene Therapy for Degenerative Retinal Diseases Fronts Teaser Modifier gene (NR2E3), a potential gene agnostic therapeutic, could reverse inherited retinal dystrophies (IRDs) with multiple gene mutations Sponsored by Ocugen